Can dacomitinib be used if erlotinib is resistant?

Erlotinib and dacomitinib are both targeted drugs against the epidermal growth factor receptor (EGFR), but they belong to different generations. Erlotinib is a first-generation EGFR inhibitor, while dacomitinib is a second-generation drug. When resistance to erlotinib occurs, whether dacomitinib can be used as an alternative treatment is a question worth exploring.

Dacomitinib is a second-generation EGFR inhibitor. Its pharmacological effect is mainly through irreversible binding to the EGFR kinase region, thereby inhibiting the proliferation of tumor cells. Compared with first-generation drugs, dacomitinib has higher affinity and selectivity and can block EGFR signaling more effectively. In addition, dacomitinib has also shown inhibitory effects on HER2 and HER4, which may provide it with a broader therapeutic spectrum.

When resistance to erlotinib occurs, it usually means that tumor cells have found a way to bypass EGFR inhibition. At this point, switching to another EGFR inhibitor may be an effective treatment strategy. Due to its unique pharmacological effects and higher affinity, dacomitinib may still be effective against tumor cells that have become resistant to erlotinib.

According to clinical research data, dacomitinib has shown significant efficacy in the first-line treatment of patients with EGFR mutated non-small cell lung cancer. For example, in the ARCHER 1050 trial, dacomitinib significantly extended patients' progression-free survival (PFS) and overall survival (OS) compared with the first-generation drug gefitinib. These data indicate that dacomitinib is effective in patients with EGFR mutations.

Before deciding to use dacomitinib, patients are advised to undergo genetic testing to confirm the specific mechanism of resistance. If resistance is caused by the T790M mutation, then the third generation EGFRInhibitors such as osimertinib may be a better choice. However, if the mechanism of resistance is not related to T790M, then dacomitinib may be a reasonable alternative treatment option.